La Jolla Pharmaceutical (NASDAQ:LJPC) Director Laura L. Douglass sold 10,000 shares of the firm’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $32.32, for a total value of $323,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
La Jolla Pharmaceutical (LJPC) traded up $0.68 during trading on Wednesday, reaching $33.85. The company had a trading volume of 409,334 shares, compared to its average volume of 594,634. The stock has a market cap of $749.62, a PE ratio of -6.64 and a beta of 1.63. La Jolla Pharmaceutical has a 1 year low of $16.71 and a 1 year high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.05. equities analysts expect that La Jolla Pharmaceutical will post -4.91 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its position in La Jolla Pharmaceutical by 11.6% during the 2nd quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares in the last quarter. Jane Street Group LLC purchased a new stake in La Jolla Pharmaceutical during the 3rd quarter worth about $200,000. Trexquant Investment LP purchased a new stake in La Jolla Pharmaceutical during the 3rd quarter worth about $217,000. Voya Investment Management LLC purchased a new stake in La Jolla Pharmaceutical during the 2nd quarter worth about $243,000. Finally, GSA Capital Partners LLP purchased a new stake in La Jolla Pharmaceutical during the 3rd quarter worth about $309,000.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.